Slide A Vision for a
Life Sciences & Biotechnology Strategy
READ MORE EUROPABIO MANIFESTO Unleashing the full potential of Life Sciences and Biotechnology in Europe
February 24, 2021

European Health Emergency Preparedness and Response Authority (HERA) Consultation – EuropaBio’s Feedback

February 15, 2021

The Business of Biotechnology: Growing for Europe’s tomorrow

February 12, 2021

EuropaBio and Alexion: RARE Conversations (Take Two) Keeping Rare Disease Patients In The Centre Of Discussion

February 12, 2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

February 2, 2021

Measuring the economic footprint of the Biotechnology Industry in Europe (WifOR Study)

January 29, 2021

Building a European Health Union

January 28, 2021

European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation

January 20, 2021

Revision of the EU legislation on medicines for children and rare diseases

November 30, 2020

Call for more effective EU regulation of Clinical Trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

November 25, 2020

EuropaBio Statement on the EU Pharmaceutical Strategy

November 2, 2020

EuropaBio announces Dr. Claire Skentelbery as new Director General of the Association

October 20, 2020

EU ATMP Hospital Exemption

October 20, 2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

October 19, 2020

Application of the ATMP Hospital Exemption in the EU

October 2, 2020

#EFIB2020 goes digital – EuropaBio hosts 13th annual European Industrial Biotechnology and Bioeconomy Conference

September 30, 2020

EuropaBio Patient engagement with the European Medicines Agency

September 3, 2020

Novartis’s Andrew Topen appointed as new Chairman of EuropaBio

August 13, 2020

Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations

August 3, 2020

Joint Statement on the Health Innovation Partnership Proposal

July 30, 2020

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

July 30, 2020

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

July 30, 2020

EuropaBio response to the Work Programme of the eHealth Stakeholder Group

July 15, 2020

EuropaBio position paper on the Farm to Fork Strategy

June 30, 2020

EuropaBio observations in response to Europe’s Beating Cancer Plan

 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe

FOLLOW US HERE


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


facebook
twitter
instagram
linkedin
youtube
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
February 24, 2021

European Health Emergency Preparedness and Response Authority (HERA) Consultation – EuropaBio’s Feedback

On February 24th, EuropaBio submitted its feedback to the HERA Consultation.
February 15, 2021

The Business of Biotechnology: Growing for Europe’s tomorrow

Read EuropaBio Report ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’
February 12, 2021

EuropaBio and Alexion: RARE Conversations (Take Two) Keeping Rare Disease Patients In The Centre Of Discussion

On February 4th, Alexion continued its RareConversations event series in cooperation with EuropaBio.
February 12, 2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
February 2, 2021

Measuring the economic footprint of the Biotechnology Industry in Europe (WifOR Study)

The purpose of this study is to estimate the economic impact of the production activities of European enterprises applying biotechnology in their research and manufacturing processes.
January 29, 2021

Building a European Health Union

EuropaBio welcomes the European Health Union plan. The EU has indeed a critical role to play in public health and better crisis preparedness to address serious cross-border health threats and improving crisis management capacity.
January 28, 2021

European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation

Read the European Biotech Associations Letter to the European Commission regarding the ongoing evaluation of the Orphan Medicinal Products Regulation.
January 20, 2021

Revision of the EU legislation on medicines for children and rare diseases

Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
November 30, 2020

Call for more effective EU regulation of Clinical Trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

Call for more effective EU regulation of clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms
November 25, 2020

EuropaBio Statement on the EU Pharmaceutical Strategy

EuropaBio looks forward to working closely with the European institutions to ensure the Pharmaceutical Strategy delivers for European patients and establishes a framework that enables a successful life sciences sector for the medium to long-term.
November 2, 2020

EuropaBio announces Dr. Claire Skentelbery as new Director General of the Association

EuropaBio announces Dr. Claire Skentelbery as new Director General of the Association.
October 20, 2020

EU ATMP Hospital Exemption

By putting forward these recommendations, EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
October 20, 2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
October 19, 2020

Application of the ATMP Hospital Exemption in the EU

EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
October 2, 2020

#EFIB2020 goes digital – EuropaBio hosts 13th annual European Industrial Biotechnology and Bioeconomy Conference

As Europe looks to the implementation of the EU Green Deal and a sustainable post-COVID future, this year’s conference will highlight how industrial biotechnology and bio-based innovation can play a key role in the transition to a more sustainable and circular economy.
Become a member